FEATURED COMPANIES
- Alimera Sciences
- Ampio Pharmaceuticals
- Novartis International Ag
- Ophthotech Corporation
- MORE
Macular edema is a condition in which the retinal layers around the fovea is accumulated by the fluid that leads to the vision impairment and also might lead to the vision loss. Macular edema can be of two types, namely cystoid macular edema and diabetic macular edema. In addition to this, the macular degeneration is a condition in which the loss of vision occurs due to the retinal damage and it majorly affects adults (>50 years). Macular degeneration is a painless disease condition that leads to the loss of central vision. Macular degeneration is of two types, namely wet macular degeneration and dry macular degeneration. Growing aging population has increasingly become an issue that leads to the growing number of macular edema and degeneration case, contributing to the growth of the market. The therapies such as anti-vascular endothelial growth factor drugs for the treatment of diabetic macular edema and Lucentis (ranibizymab) & Avastin drugs for the macular degeneration have played a significant role in the growth of global macular edema and degeneration market.
Global macular edema and macular degeneration market is segmented based on the types of macular edema and macular degeneration. In addition to this, the Macular edema market is segmented based on its type, namely cystoid macular edema (CME) and diabetic macular edema (DME). Macular degeneration market is segmented based on its types such as dry age-related macular degeneration (Dry AMD) and wet age -related macular degeneration (wet AMD). The global macular edema and degeneration market is classified based on the treatment into macular edema diagnosis and macular degeneration diagnosis. Based on geography, the market is segmented into North America, Europe, Asia-pacific and LAMEA.
Companies such as Novartis, Roche, Bayer, Allergan, Ampio Pharmaceuticals and valeant Pharmaceuticals International are the leading players operating in the market. Leading players such as Bayer and Novartis are focusing on the joint venture strategy to develop new treatment option for the macular edema and macular degeneration.
KEY BENEFITS
- Market analysis based on the current market scenario and expected future trends to enable stakeholders take strategic decision
- Market estimation for techniques and geographic segment is derived from current market scenario and expected market trends
- Market attractiveness analysis has been included for the treatment types and geographic regions with detailed analysis of factors responsible for rapid growth of the market segments
- The report provides analysis of key drivers, restrains and opportunities of macular edema and degeneration market including its impact on the global market
- Value chain analysis, Porter’s five force model, top investment pockets (GE9 Cell Matrix) are analyzed and presented in detail in the report so that the decision makers can receive clear picture of macular edema and degeneration market
- The projections in the report are made by analyzing the current market trends and future market potential for the period of 2014-2021 in terms of value
Market Segmentation
Macular edema and degeneration market is segmented based on its types, treatment and geography.
MARKET BY TYPE
- Macular Edema
- Cystoid macular edema (CME)
- Diabetic macular edema (DME)
- Macular Degeneration
- Dry age-related macular degeneration
- Wet age-related macular degeneration
MARKET BY TREATMENT
- Drug therapy
- Laser treatment
- Implantable telescope
MARKET BY GEOGRAPHY
- North America
- Europe
- Asia-Pacific
- LAMEA
* This report will be delivered in 12 Business Days. *
FEATURED COMPANIES
- Alimera Sciences
- Ampio Pharmaceuticals
- Novartis International Ag
- Ophthotech Corporation
- MORE
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/ TOP PLAYER POSITIONING, 2017
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CYSTOID MACULAR EDEMA
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. DIABETIC MACULAR EDEMA
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. DRY AGE-RELATED MACULAR DEGENERATION
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. WET AGE-RELATED MACULAR DEGENERATION
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY TREATMENT
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DRUG THERAPY
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. LASER TREATMENT
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. OTHERS
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. AMBULATORY SURGICAL CENTERS & CLINICS
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7 MACULAR EDEMA & MACULAR DEGENERATION MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends, growth factors & opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S. macular edema & macular degeneration market size and forecast
7.2.2.1.1. U.S. macular edema & macular degeneration market, by type
7.2.2.1.2. U.S. macular edema & macular degeneration market, by treatment
7.2.2.1.3. U.S. macular edema & macular degeneration market, by end user
7.2.2.2. Canada macular edema & macular degeneration market size and forecast
7.2.2.2.1. Canada macular edema & macular degeneration market, by type
7.2.2.2.2. Canada macular edema & macular degeneration market, by treatment
7.2.2.2.3. Canada macular edema & macular degeneration market, by end user
7.2.2.3. Mexico macular edema & macular degeneration market size and forecast
7.2.2.3.1. Mexico macular edema & macular degeneration market, by type
7.2.2.3.2. Mexico macular edema & macular degeneration market, by treatment
7.2.2.3.3. Mexico macular edema & macular degeneration market, by end user
7.2.3. North America macular edema & macular degeneration market, by type
7.2.4. North America macular edema & macular degeneration market, by treatment
7.2.5. North America macular edema & macular degeneration market, by end user
7.3. EUROPE
7.3.1. Key market trends, growth factors & opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany macular edema & macular degeneration market size and forecast
7.3.2.1.1. Germany macular edema & macular degeneration market, by type
7.3.2.1.2. Germany macular edema & macular degeneration market, by treatment
7.3.2.1.3. Germany macular edema & macular degeneration market, by end user
7.3.2.2. France macular edema & macular degeneration market size and forecast
7.3.2.2.1. France macular edema & macular degeneration market, by type
7.3.2.2.2. France macular edema & macular degeneration market, by treatment
7.3.2.2.3. France macular edema & macular degeneration market, by end user
7.3.2.3. UK macular edema & macular degeneration market size and forecast
7.3.2.3.1. UK macular edema & macular degeneration market, by type
7.3.2.3.2. UK macular edema & macular degeneration market, by treatment
7.3.2.3.3. UK macular edema & macular degeneration market, by end user
7.3.2.4. Italy macular edema & macular degeneration market size and forecast
7.3.2.4.1. Italy macular edema & macular degeneration market, by type
7.3.2.4.2. Italy macular edema & macular degeneration market, by treatment
7.3.2.4.3. Italy macular edema & macular degeneration market, by end user
7.3.2.5. Spain macular edema & macular degeneration market size and forecast
7.3.2.5.1. Spain macular edema & macular degeneration market, by type
7.3.2.5.2. Spain macular edema & macular degeneration market, by treatment
7.3.2.5.3. Spain macular edema & macular degeneration market, by end user
7.3.2.6. Rest of Europe macular edema & macular degeneration market size and forecast
7.3.2.6.1. Rest of Europe macular edema & maculardegeneration market, by type
7.3.2.6.2. Rest of Europe macular edema & maculardegeneration market, by treatment
7.3.2.6.3. Rest of Europe macular edema & maculardegeneration market, by end user
7.3.3. Europe macular edema & macular degeneration market, by type
7.3.4. Europe macular edema & macular degeneration market, by treatment
7.3.5. Europe macular edema & macular degeneration market, by end user
7.4. ASIA-PACIFIC
7.4.1. Key market trends, growth factors & opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan macular edema & macular degeneration market sizeand forecast
7.4.2.1.1. Japan macular edema & macular degenerationmarket, by type
7.4.2.1.2. Japan macular edema & macular degenerationmarket, by treatment
7.4.2.1.3. Japan macular edema & macular degenerationmarket, by end user
7.4.2.2. China macular edema & macular degeneration market sizeand forecast
7.4.2.2.1. China macular edema & macular degenerationmarket, by type
7.4.2.2.2. China macular edema & macular degenerationmarket, by treatment
7.4.2.2.3. China macular edema & macular degenerationmarket, by end user
7.4.2.3. Australia macular edema & macular degeneration marketsize and forecast
7.4.2.3.1. Australia macular edema & maculardegeneration market, by type
7.4.2.3.2. Australia macular edema & maculardegeneration market, by treatment
7.4.2.3.3. Australia macular edema & maculardegeneration market, by end user
7.4.2.4. India macular edema & macular degeneration market sizeand forecast
7.4.2.4.1. India macular edema & macular degenerationmarket, by type
7.4.2.4.2. India macular edema & macular degenerationmarket, by treatment
7.4.2.4.3. India macular edema & macular degenerationmarket, by end user
7.4.2.5. South Korea macular edema & macular degenerationmarket size and forecast
7.4.2.5.1. South Korea macular edema & maculardegeneration market, by type
7.4.2.5.2. South Korea macular edema & maculardegeneration market, by treatment
7.4.2.5.3. South Korea macular edema & maculardegeneration market, by end user
7.4.2.6. Rest of Asia-Pacific macular edema & maculardegeneration market size and forecast
7.4.2.6.1. Rest of Asia-Pacific macular edema & maculardegeneration market, by type
7.4.2.6.2. Rest of Asia-Pacific macular edema & maculardegeneration market, by treatment
7.4.2.6.3. Rest of Asia-Pacific macular edema & maculardegeneration market, by end user
7.4.3. Asia-Pacific macular edema & macular degeneration market, bytype
7.4.4. Asia-Pacific macular edema & macular degeneration market, bytreatment
7.4.5. Asia-Pacific macular edema & macular degeneration market, byend user
7.5. LAMEA
7.5.1. Key market trends, growth factors & opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil macular edema & macular degeneration market sizeand forecast
7.5.2.1.1. Brazil macular edema & macular degenerationmarket, by type
7.5.2.1.2. Brazil macular edema & macular degenerationmarket, by treatment
7.5.2.1.3. Brazil macular edema & macular degenerationmarket, by end user
7.5.2.2. Saudi Arabia macular edema & macular degenerationmarket size and forecast
7.5.2.2.1. Saudi Arabia macular edema & maculardegeneration market, by type
7.5.2.2.2. Saudi Arabia macular edema & maculardegeneration market, by treatment
7.5.2.2.3. Saudi Arabia macular edema & maculardegeneration market, by end user
7.5.2.3. South Africa macular edema & macular degenerationmarket size and forecast
7.5.2.3.1. South Africa macular edema & maculardegeneration market, by type
7.5.2.3.2. South Africa macular edema & maculardegeneration market, by treatment
7.5.2.3.3. South Africa macular edema & maculardegeneration market, by end user
7.5.2.4. Rest of LAMEA. macular edema & macular degeneration market size and forecast
7.5.2.4.1. Rest of LAMEA macular edema & macular degeneration market, by type
7.5.2.4.2. Rest of LAMEA macular edema & macular degeneration market, by treatment
7.5.2.4.3. Rest of LAMEA macular edema & macular degeneration market, by end user
7.5.3. LAMEA macular edema & macular degeneration market, by type
7.5.4. LAMEA macular edema & macular degeneration market, by treatment
7.5.5. LAMEA macular edema & macular degeneration market, by end user
CHAPTER 8 COMPANY PROFILES
8.1. AMPIO PHARMACEUTICALS
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. ALIMERA SCIENCES
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. NOVARTIS INTERNATIONAL AG
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. REGENERON PHARMACEUTICALS, INC.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
CHAPTER 8 COMPANY PROFILES
8.1. AMPIO PHARMACEUTICALS
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. ALIMERA SCIENCES
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. NOVARTIS INTERNATIONAL AG
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. REGENERON PHARMACEUTICALS, INC.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.9. OPHTHOTECH CORPORATION
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
LOADING...
- Alimera Sciences
- Ampio Pharmaceuticals
- Novartis International Ag
- Ophthotech Corporation
- Regeneron Pharmaceuticals, Inc.
- Valeant Pharmaceuticals International, Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
